Bristol Myers Squibb Company $BMY Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 5.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 296,909 shares of the biopharmaceutical company’s stock after selling 18,333 shares during the quarter. New York Life Investment Management LLC’s holdings in Bristol Myers Squibb were worth $13,391,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at about $1,554,154,000. Charles Schwab Investment Management Inc. grew its stake in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after purchasing an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Bristol Myers Squibb by 428.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after purchasing an additional 9,171,098 shares during the period. Man Group plc raised its stake in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Bristol Myers Squibb by 142.8% during the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after purchasing an additional 4,961,869 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BMY. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Piper Sandler reissued an “overweight” rating and set a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Guggenheim restated a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Friday. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $46.00 to $65.00 in a research report on Wednesday, January 7th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $59.20.

Bristol Myers Squibb Stock Performance

BMY opened at $60.75 on Tuesday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The stock has a market cap of $123.67 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.19 and a beta of 0.29. The stock’s 50 day simple moving average is $54.57 and its 200 day simple moving average is $49.12. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.